Pharma Update
Off-the-shelf CAR-Ts for hematologic malignancies
Highly differentiated new generation of fully allogeneic CAR-Ts
Long-lived self-renewing stem
cell memory T cells
TSCM Cell
Stem cell memory
High-fidelity, proprietary gene
editing technology
POSEIDA
THERAPEUTICS
Cost, scale and reach
Self-renewing
•
Long-lived
•
Multipotent
•
Healthy donor
derived
MHC I knock-out
TCR knock-out
Roche
• T SCM - ideal cell type for CAR-T due to
greater safety and durability
• piggy BacⓇ - superior non-viral gene
insertion technology
Addressing both Graft v Host and Host
v Graft alloreactivity with Cas-CLOVER™
Gene Editing
• Proprietary booster molecule enables
potential to deliver 100's of doses
translating into lower cost, lower wait
time and broader patient reach
Ph I open-label dose-escalation study of P-BCMA-ALLO1 in MM ongoing: Early signs of efficacy and favorable tolerability profile
P-CD19CD20-ALLO1 IND approved Q2 2023, Ph I in B-cell malignancies expected to start early 2024
Additional allogeneic CAR-Ts in development for MM and AML
•
Program in partnership with Poseida; Kocoglu M et al., ESMO I-O 2022; IND=investigational new drug application; CAR-T-chimeric antigen receptor T-cell; MM-multiple myeloma; AML-Acute myeloid leukemia
24
94View entire presentation